**Core tip:** The primary characteristic of pancreatic adenocarcinoma is the presence of an extensive desmoplastic stroma around neoplastic cells. In this study, we aim to briefly review the primary structural properties of pancreatic cancer (PC) stroma and its interaction with cancer cells and summarize the current status of anti-stromal therapies in the management of metastatic PC.

INTRODUCTION
============

The primary characteristic of pancreatic adenocarcinoma is the presence of an extensive desmoplastic stroma around neoplastic cells in both primary and metastatic lesions\[[@B1]\]. The structural organization of stroma is not entirely different from those in other solid tumors; in fact, it is a mixture of cellular and acellular \[extracellular matrix (ECM) proteins\] elements\[[@B2]\]. However, in contrast to several other solid tumors, stromal elements can occupy ≥ 80% of the total tumor volume in most pancreatic cancer (PC) cases\[[@B3]\].

Abundant accumulation of fibrous proteins, primarily collagen (types I and III), fibronectin, and secreted protein acidic and rich in cysteine (SPARC) in the ECM offers exceptional mechanical properties of pancreatic adenocarcinoma stroma, including considerably enhanced stiffness and reduced elasticity\[[@B4]\]. In addition, increased deposition of another crucial ECM element hyaluronan (HA) in the tumor stroma creates substantial swelling stress, which progressively increases the interstitial fluid pressure\[[@B5]\]. The occurrence of this condition besides increased tissue stiffness compresses intratumoral blood vessels, resulting in tumor hypoperfusion and hypoxia. Reportedly, hypoperfusion drastically reduces intratumoral delivery of chemotherapy drugs and, consequently, their efficacy\[[@B6],[@B7]\]. Hypoxia confers a survival advantage for neoplastic cells and potentiates their invasion, stemness, and metastatic capacity primarily through the hypoxia-inducible factor-1α--mediated hepatocyte growth factor/c-Met pathway activation\[[@B8],[@B9]\]. Moreover, hypoxia compromises the efficacy of radiotherapy.

In PC, ECM proteins are primarily produced by a distinct type of stromal cells called activated pancreatic stellate cells (PSCs). PSCs phenotypically resemble myofibroblasts and exhibit the α-smooth muscle actin expression. However, in contrast to myofibroblasts, PSCs are positively stained for selective markers such as desmin and glial fibrillary acidic protein. They also demonstrate increased proliferation and migration ability relative to myofibroblasts, and can produce large amounts of collagen and other ECM proteins\[[@B10],[@B11]\]. PSCs possess the adequate capacity to interact with cancer cells and other stromal cells (*i.e*., immune cells, inflammatory cells, and endothelial cells) to extend stroma and promote cancer progression. Thus, both cellular (especially PSCs) and acellular (especially HA) components of PC stroma have been held accountable for unsatisfactory treatment outcomes in patients with PC. This condition has encouraged PC researchers to elucidate the potential beneficial effects of stroma disrupting agents alone or in combination with standard chemotherapy in the treatment of PC (Figure [1](#F1){ref-type="fig"}).
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ROLES OF PSCS IN PC PROGRESSION
===============================

Despite being debatable, activated PSCs are deliberated to originate from their inactive (quiescent) forms that are primarily found in the periacinar space of the exocrine pancreas\[[@B12]\]. Reportedly, inflammatory (*i.e*., interleukin-1 and interleukin-6, and tumor necrosis factor-α) and mitogenic (*i.e*., transforming growth factor and platelet-derived growth factor) cytokines secreted by cancer cells are accountable for the PSC activation\[[@B13]-[@B18]\]. Perhaps, some intracellular pathways, including p38 mitogen-activated protein kinase, RhoA/Rho kinase, and cyclooxygenase-2, could play a vital role in this process\[[@B18]-[@B22]\].

In pancreatic carcinogenesis, activated PSCs seemingly serve two primary functions, to produce ECM molecules and regulate the formation of desmoplastic reaction and enable cancer cell proliferation and invasion\[[@B13]\]. The direct cell-to-cell contact between PSCs and PC cells has been demonstrated to result in the activation of the Notch signaling pathway in both cell types\[[@B23]\]. The Notch signaling plays a vital role in the proliferation, migration, differentiation, and apoptosis of cancer cells\[[@B24],[@B25]\]. Apparently, PSCs can activate the mitogen-activated protein kinase and Akt pathways in tumor cells, causing enhanced tumor growth and metastasis\[[@B26]\]. PSCs secrete matrix metalloproteinase-2 into the tumor microenvironment in response to extracellular matrix metalloproteinase inducer (EMMPRIN) secreted by cancer cells to facilitate the tissue invasion and metastasis\[[@B27]\]. In addition, PSCs can accompany cancer cells to distant sites, where they stimulate angiogenesis, cancer cell seeding, survival, and proliferation and, thus, facilitate the metastasis formation\[[@B28]\]. Furthermore, PSCs can indirectly protect cancer cells from the immune system attack. A study demonstrated that PSCs secreted CXCL12 chemokine and sequestered CD8^+^ T cells to reduce their accumulation in the juxtatumoral compartments\[[@B29]\]. Mace et al\[[@B30]\] suggested that PSC-derived cytokines, such as interleukin-6, cause myeloid-derived suppressor cell expansion in the stroma, thereby indirectly inducing immune cell dysfunction.

Preclinical data indicated that PCSs might enhance stem-cell like phenotypes in PC cells\[[@B31]\]. Indirect co-culture of PSCs with PC cells increased the spheroid-forming capacity of tumor cells, and induced the expression of stem cell-related genes including Nestin, ABCG2 and LIN28\[[@B31]\]. Lonardo et al\[[@B32]\] showed that the secretion of transforming growth factor-β superfamily members Nodal and Activin from PCSs significantly promotes the self-renewal capacity and invasiveness of PC stem cells.

Recent studies have shown that extracellular vesicles (also known as exosomes) derived from PSCs may play a role in the progression of PC\[[@B33],[@B34]\]. Takikawa et al\[[@B34]\] reported that immortalized human PSCs produce exosomes containing numerous microRNAs (miRNAs) that can induce chemokine gene expression in PC cell lines resulted in increased proliferation and migration. Leca et al\[[@B35]\] found that annexin 6A/receptor-related protein 1/thrombospondin-1 complex-containing exosomes released by PSCs could increase PC cell aggressiveness under physiopathologic conditions. In addition, exosomes have been suggested to contribute to chemoresistance of PC cells by promoting reactive oxygen species detoxification and by decreasing gemcitabine-metabolizing enzyme activity\[[@B36]\].

POTENTIAL THERAPEUTIC STRATEGIES TARGETING PSCS
===============================================

Vitamin D and A analogs
-----------------------

Preclinical studies have reported that the PSC activation can be restricted or reversed by pharmacological interventions leading to substantial modulation of the tumor stroma\[[@B37],[@B38]\]. Apparently, PSCs express higher levels of vitamin D receptors\[[@B37]\]. Sherman et al\[[@B37]\] reported that a potent vitamin D analog calcipotriol treatment decreased the expression of activation and cancer signature genes in cultured PSCs, stimulated lipid droplet formation, and reduced the α-smooth muscle actin expression, signifying their inactivation; this correlated with a decline in stromal inflammation and fibrosis. In addition, the authors compared the efficacy of gemcitabine plus calcipotriol treatment with gemcitabine alone in the KPC model of PC and reported that the combination therapy increased the intratumoral uptake of gemcitabine, reduced tumor volume, and exhibited 57% improvement in animal survival compared with gemcitabine monotherapy. These findings suggested that the tumor stromal modulation (reprogramming) by inactivating PSCs could be a reasonable treatment strategy for PC. Paricalcitol, a synthetic vitamin D analog is currently being tested in combination with conventional chemotherapy or immunotherapy in the treatment of metastatic PC (Table [1](#T1){ref-type="table"}).

###### 

Summary of existing studies evaluating the efficacy of anti-stromal agents in the treatment of metastatic pancreatic cancer

  **Agent**                                                                                                   **Target**                    **Treatment arm (s)**                                                 **Type of study**   **National clinical trial number**                                            **Status**   **Results**
  ----------------------------------------------------------------------------------------------------------- ----------------------------- --------------------------------------------------------------------- ------------------- ----------------------------------------------------------------------------- ------------ ----------------------------------------------------------------------------------------------------------
  Paricalcitol                                                                                                Vitamin D metabolic pathway   Gemcitabine and nab-paclitaxel plus paricalcitol or placebo           Phase I/II          NCT03520790                                                                   Recruiting   
  Nab-paclitaxel, cisplatin and gemcitabine plus paricalcitol                                                 Phase II                      NCT03415854                                                           Recruiting                                                                                                     
  Nivolimumab[1](#T1FN1){ref-type="table-fn"}, nab-paclitaxel, cisplatin, and gemcitabine plus paricalcitol   Phase II                      NCT02754726                                                           Recruiting                                                                                                     
  Pembrolizumab[1](#T1FN1){ref-type="table-fn"} plus paricalcitol or placebo                                  Phase II                      NCT03331562                                                           Recruiting                                                                                                     
  All trans retinoic acid                                                                                     Pancreatic stellate cells     Gemcitabine and nab-paclitaxel plus all trans retinoic acid           Phase I             NCT03307148                                                                   Recruiting   
  Vismodegib                                                                                                  Hedgehog signaling            Gemcitabine plus vismodegib or placebo                                Phase I/II          NCT0106422                                                                    Completed    Vismodegib did not improve ORR, PFS and OS
  IPI-926                                                                                                     Hedgehog signaling            FOLFIRINOX plus IPI-926                                               Phase I             NCT01383538                                                                   Completed    The combination treatment was safe but IP-926 was not beneficial
  Gemcitabine plus IPI-926 or placebo                                                                         Phase I/II                    NCT01130142                                                           Completed           The combination treatment was well tolerated, and showed promising activity                
  PEGPH20                                                                                                     Hyaluronic acid               Gemcitabine and nab-paclitaxel plus PEGPH20 *vs* chemotherapy alone   Phase II            NCT01839487                                                                   Completed    PEGPH20 significantly improved PFS, especially in patients having tumors with high-level hyaluronic acid
  Gemcitabine and nab-paclitaxel plus PEGPH20 or placebo[2](#T1FN2){ref-type="table-fn"}                      Phase III                     NCT02715804                                                           Recruiting                                                                                                     
                                                                                                                                            Modified FOLFIRINOX plus PEGPH20 *vs* chemotherapy alone              Phase I/II          NCT01959139                                                                   Closed       PEGPH20 was found to have a detrimental effect on OS

Nivolimumab and Pembrolizumab: PD-1-targeted T-cell checkpoint inhibitors;

This study included only patients whose tumors had high levels of hyaluronic acid. ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival; FOLFIRINOX: 5-fluorouracil, irinotecan and, oxaliplatin.

Quiescent PSCs store vitamin A-containing lipid droplets in their cytoplasm, which are lost during the activation process. Research has revealed that restoring vitamin A in PCSs by using vitamin A metabolites could reprogram these cells to a quiescent phase\[[@B39]\]. Jaster et al\[[@B40]\] reported that all-trans-retinoic acid (ATRA) could impede the proliferation and collagen synthesis of PSCs isolated from rat pancreas by hindering the AP-1 activation. Of note, AP-1 is a transcription factor that regulates cell growth, differentiation, and survival. McCarroll et al\[[@B41]\] described that ATRA and 9-cis retinoic acid could avert the activation of cultured activated PSCs by inhibiting the mitogen-activated protein kinase signaling pathway, and decreased collagen I, fibronectin, and laminin expression in these cells. In addition, a study reported that the reduction of Wnt-B-catenin signaling by ATRA in PC cells resulted in slower tumor progression\[[@B42]\]. Furthermore, Chronopoulos et al\[[@B43]\] determined that ATRA could reduce the actomyosin-dependent contractility, mechanosensing, and migration of PSCs in a retinoic acid receptor (RAR)-β--dependent manner. Likewise, Sarper et al\[[@B39]\] also reported similar findings. Overall, reprogramming of PSCs using vitamin A metabolites, such as ATRA or selective RAR-β agonists, in a clinical setting could open new avenues in the treatment of PC (Table [1](#T1){ref-type="table"}).

Antifibrotic agents
-------------------

Kozono et al\[[@B44]\] reported that the antifibrotic anti-inflammatory agent pirfenidone could impede the proliferation, invasiveness, migration, and ECM protein synthesis ability of PSCs in vitro. In mice bearing orthotopically implanted PC and PSCs, pirfenidone was shown to suppress the tumor growth and metastasis formation and displayed a synergistic antitumor effect with gemcitabine. In addition, Suklabaidya et al\[[@B45]\] reported that the effects of pirfenidone could be potentiated when co-administered with antioxidant N-acetyl cysteine. Thus, the potential effects of pirfenidone alone or in combination with N-acetyl cysteine in PC necessitate further assessment in human subjects.

***Angiotensin* II *inhibitors***

Previously, preclinical studies have demonstrated that angiotensin II plays a promoting role in the PSC proliferation, which seems to be controlled by induction of the Smad7 expression through a protein kinase C--dependent pathway, resulting in the inhibition of TGF-β1 signaling\[[@B46]\]. On the basis of these findings, several angiotensin II receptor antagonists have been investigated as a potential strategy to reduce PSC-mediated stromal fibrosis. Yamada et al\[[@B47]\] reported that candesartan considerably reduces the PSC proliferation and decreases the histological score of experimental pancreatic inflammation and fibrosis formation by avoiding the activation of TGF-β1 signaling. In addition, Masamune et al\[[@B48]\] investigated the effects of another angiotensin II antagonist, olmesartan, on PC-associated fibrosis in a subcutaneous xenograft model. Apparently, olmesartan could inhibit the PSC proliferation and collagen Iproduction, resulting in the tumor growth suppression. Nevertheless, further preclinical data are warranted before advancing these agents to clinical trials.

Upregulation of microRNAs in PSCs
---------------------------------

miRNAs are small noncoding RNA molecules involved in RNA silencing and post-transcriptional gene expression regulation. A study reported that miR-21, a profibrotic miRNA, is upregulated in cancer--associated myofibroblasts and PSCs isolated from resected PC tissues\[[@B49]\]. In addition, PC cells have been assumed to induce miR-21 upregulation in these cells, expediting their invasion and metastasis\[[@B49]\]. Donahue et al\[[@B50]\] reported that a high stromal miR-21 level correlated with worse overall survival in patients with PC who received adjuvant 5-fluorouracil but not gemcitabine. A meta-analysis showed that miR-21 upregulation in tumor tissue and blood samples of patients with PC was significantly associated with poorer overall survival, disease-free survival, and progression-free survival. A significant correlation was detected between miR-21 expression and lymph node status and tumor grade\[[@B51]\]. Frampton et al\[[@B52]\] reported that, in addition to miR-21, other miRNAs, such as miR-10b, miR-34, miR-155, and miR-203 also appear to have prognostic significance in pancreatic ductal adenocarcinoma. The dysregulation of miR-320a, miR-365, miR-200, and miR-210 has been found to be involved in tumor invasion, epithelial to mesenchymal transition development, and chemotherapeutic drug resistance in PC\[[@B53]\]. Thus, silencing of specific miRNAs by chemically modified antisense oligonucleotides could be a novel therapeutic intervention for PC.

Inhibition of hedgehog signaling in PSCs
----------------------------------------

Bailey et al\[[@B54]\] were the first to report that sonic hedgehog (Hh) ligands secreted by PC can activate the canonical Hh signaling pathway in PSCs, resulting in their activation, differentiation, and proliferation. In addition, sonic Hh has been shown to promote desmoplasia in orthotopic mouse models of PC, and inhibiting sonic Hh with monoclonal antibody 5E1 markedly decreased the degree of desmoplasia\[[@B54]\].

In their groundbreaking preclinical study, Olive et al\[[@B55]\] assessed the effects of orally administered smoothened antagonist IPI-926 (or saridegib, a derivative of Hh inhibitor cyclopamine) on the tumor stroma and intratumoral uptake of gemcitabine in pancreatic tumor-bearing KPC mice. The result revealed that IPI-926 treatment considerably reduced the proliferation of stromal myofibroblasts, considerably depleted stromal components, and resulted in a transient increase in the intratumoral vascular density and intratumoral concentration of gemcitabine, facilitating transient disease stabilization. On the basis, in part, of these findings, a phase I/III clinical study was commenced to assess the safety and efficacy of IPI-926 and gemcitabine combination treatment in metastatic PC\[[@B56]\] (Table [1](#T1){ref-type="table"}). The initial outcomes revealed that this combination was well tolerated and resulted in a partial response in 5 of 16 patients in the phase 1b portion of the study.

In another phase I study, IPI-926 was used in combination with 5-fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX), a potent and intensive chemotherapy regimen, in the first-line treatment of advanced PC\[[@B57]\]. The preliminary outcomes revealed that the unsubstantiated overall response rate was 66.7%, and that treatment-related toxicities were acceptable and tolerable. However, the initial findings of a phase Ib/II study conducted by Catenacci et al\[[@B58]\] questioned the efficacy of Hh inhibition in advanced PC. The authors evaluated the synergistic activity of vismodegib, a small-molecule inhibitor of smoothened, and gemcitabine in patients with metastatic PC. They observed no safety concerns in the phase 1b portion of the study. In the phase II portion of the study, they randomized 106 patients into gemcitabine plus vismodegib or gemcitabine plus placebo groups, but observed no significant differences in the progression-free (*P* = 0.30) and overall survival (*P* = 0.84) between the two treatment groups. Moreover, the response rates were not significantly different (Table [1](#T1){ref-type="table"}).

OTHER TARGETABLE ELEMENTS OF STROMA
===================================

Hyaluronan
----------

Reportedly, the PC stroma might comprise a considerable amount of HA, which is a high-molecule glycosaminoglycan comprising repeating units of [D]{.smallcaps}-glucuronic acid and N-acetyl-glucosamine\[[@B59],[@B60]\]. Reportedly, HA levels in PC tissue might reach 12-fold higher than that found in healthy pancreatic tissue\[[@B61]\]. In addition, PC cells typically express high levels of the primary HA receptor, CD44\[[@B62],[@B63]\]. When HA binds to CD44, four major signaling pathways activated in PC cells are as follows: RAS, Rac, MAPK, and phosphatidylinositol-3-kinase. In fact, signaling through these pathways accelerates the proliferation, epithelial-to-mesenchymal transition, stemness, and metastatic capacity of PC cells and increases their resistance against chemotherapeutic drugs\[[@B64]-[@B70]\]. Besides its significant tumor-promoting effects, HA is a crucial contributor to the impaired blood perfusion of tumor cells, increased tumor hypoxia, and, more crucially, insufficient drug delivery to the tumor, as mentioned previously\[[@B1],[@B60],[@B69],[@B70]\].

Some preclinical studies have reported that the enzymatic degradation of HA using PEGylated human recombinant hyaluronidase PH20 (PEGPH20) in genetically engineered mouse models of PC could prompt the re-expansion of collapsed tumor vessels and promote doxorubicin and gemcitabine delivery. Furthermore, the combined use of gemcitabine and PEGPH20 exhibited a synergistic effect and substantially inhibited the tumor growth, resulting in the upgraded survival of animals. Conversely, gemcitabine monotherapy only modestly affected the tumor growth compared with PEGPH20 alone\[[@B60]\]. Provenzano et al\[[@B71]\] reported similar findings and observed that PEGPH20 effectively ablated HA from metastatic deposits as with primary tumors and reinstated the vascular pattern.

Consequently, a phase 1b study by Hingorani et al\[[@B72]\] evaluated the safety and efficacy of escalating doses of intravenous PEGPH20 combined with gemcitabine in patients with metastatic PC. The treatment was well tolerated by patients (*n* = 28) and exhibited a promising clinical activity. However, patients with tumors comprising higher HA levels seemingly benefited more from this treatment than those whose tumors had lower HA levels. In addition, the median progression-free and overall survival durations were 7.2 and 13 mo for patients with high HA levels and 3.5 and 5.7 mo for patients with low HA levels, respectively. Notably, these results encouraged further clinical research.

The final outcomes of phase 2 HALO-109-202 study, in which PEGPH20 was administered together with nab-paclitaxel plus gemcitabine regimen, were presented at the 2017 American Society of Clinical Oncology Annual Meeting\[[@B73]\]. The study randomized 279 patients with untreated metastatic PC to receive either PEGPH20 plus chemotherapy (100 patients treated) or chemotherapy alone (160 patients treated). The combination therapy substantially improved the median progression-free survival (primary endpoint: 6.0 mo *vs* 5.3 mo; *P* = 0.045) in unselected patients. In HA-high patients (34% of enrolled patients), a significant increase was again noted in the progression-free survival with PEGPH20 plus chemotherapy compared with chemotherapy alone (median: 9.2 mo *vs* 5.2 mo; *P* = 0.48). However, no significant difference was observed between the two treatment arms regarding the overall survival (median: 11.5 mo *vs* 8.5 mo; HR, 0.96). Apparently, thromboembolic events pose a primary complication of PEGPH20 treatment. In the first stage of this phase 2 study, none of the patients randomized to PEGFP20 arm was provided thromboprophylaxis, and 43% of these developed thrombosis, causing a temporary cessation in the treatment. However, in the second stage, the rate of this complication was decreased to 28% with the administration of enoxaparin prophylaxis. PEGPH20 treatment was also associated with increased incidence and severity of other manageable side effects, such as painful muscle spasms, arthralgia, peripheral edema, and neutropenia. Overall, PEGPH20 is the first stroma-targeting agent that has demonstrated its efficacy in a clinical setting. Currently, a phase III study (HALO Pancreatic 301; NCT02715804) is recruiting patients with stage IV PC whose tumors have a high level of HA to validate phase II results.

In contrast, a recently presented randomized phase I/II study evaluating the efficacy of PEGPH20 and modified FOLFIRINOX in patients with metastatic PC who have a good performance status suggested that PEGPH20 can have a detrimental effect on OS (HR = 0.48). Therefore, further studies are needed to clarify whether the benefit from the use of PEGPH20 is restricted to patients treated with gemcitabine and nab-paclitaxel\[[@B74]\] .

Secreted protein acidic and rich in cysteine
--------------------------------------------

SPARC (also known as osteonectin or basement membrane protein 40) is a member of the matricellular proteins group and plays regulatory roles in cellular proliferation and adhesion. Guweidhi et al\[[@B75]\] described that primary and metastatic lesions of PC expressed SPARC 31-fold more compared with normal pancreatic tissue. In addition, PC cells fail to produce SPARC because of aberrant hypermethylation in their *SPARC* gene. Thus, almost all SPARC in PC tissue is produced by PSCs\[[@B75]-[@B78]\]. Reportedly, SPARC can increase the migration ability and invasive properties of PC cells\[[@B78]-[@B80]\]. In addition, SPARC can stimulate the MMP production in neoplastic cells, thereby enhancing their metastatic potential\[[@B75],[@B77],[@B81],[@B82]\]. Accordingly, patients with PC whose tumors contain elevated amounts of SPARC have been reported to have worse survival compared with those whose tumors contain lower SPARC levels following radical surgery or chemoradiotherapy\[[@B80],[@B83]-[@B85]\].

Owing to its high affinity for albumin, stromal SPARC, perhaps, increases the intratumoral delivery and efficacy of the chemotherapeutic drug albumin-bound paclitaxel (nab-paclitaxel) in patients with PC\[[@B86]\]. In their phase I/II study, Von Hoff et al\[[@B86]\] examined the efficacy of escalating doses of nab-paclitaxel in combination with fixed doses gemcitabine in 67 patients with previously untreated metastatic PC. The treatment resulted in an overall response rate of 48%, and the median overall survival duration of 12.2 mo. In the study, the SPARC status was assessed in 36 patients, and patients whose tumors had high SPARC expression (*n* = 19) exhibited better overall survival than patients whose tumors displayed low SPARC expression (median: 17.8 *mo vs* 8.1 mo; *P* = 0.0431). In addition, the study established a significant correlation between the stromal SPARC level and the patients' survival (*P* = 0.013). However, SPARC in tumor cells did not exert any effect on survival (*P* = 0.15). Besides, the authors assessed the treatment-related stromal changes and intratumoral penetration of the drugs in a patient-derived xenograft mouse model of PC and demonstrated that tumors resected from mice treated with gemcitabine alone demonstrated an extensive desmoplastic stroma. However, tumors in mice treated with nab-paclitaxel alone or in combination with gemcitabine exhibited the reduced stromal content, which was accompanied by dilated tumor blood vessels. Thus, the intratumoral concentration of gemcitabine was determined to be 2.8-fold higher in nab-paclitaxel plus gemcitabine-treated mice compared with mice receiving gemcitabine alone.

On the basis of these results, Von Hoff et al\[[@B87]\] conducted a phase III study in which 861 patients with metastatic PC were randomly allotted to receive either nab-paclitaxel plus gemcitabine or gemcitabine alone. Their findings established the superiority of the combination regimen over gemcitabine monotherapy. In addition, patients receiving nab-paclitaxel plus gemcitabine exhibited longer median overall survival compared with those receiving gemcitabine alone (8.5 mo *vs* 6.7 mo; *P* \< 0.001). Furthermore, they demonstrated a better response rate (23% *vs* 7%; *P* \< 0.001). Hence, it could be speculated that the tumor SPARC level could be used as a predictive marker to determine patients with advanced PC most likely to benefit from nab-paclitaxel--based chemotherapy.

CONCLUSION
==========

Despite the determination of active chemotherapeutic regimens, such as nab-paclitaxel plus gemcitabine and FOLFIRINOX, in metastatic PC, the overall treatment outcomes remain inadequate. Perhaps, stroma-depletion strategies could provide novel treatment opportunities for patients with this formidable disease. Among them, the enzymatic degradation of stromal HA by PEGPH20 is currently the only effective method in the clinical setting. After the announcement of the final outcomes of the phase III HALO Pancreatic 301 study, PEGPH20 could be incorporated into standard-of-care treatment regimens in metastatic PC. Of note, promising preclinical effects of Hh inhibitors await clinical confirmation; however, these could exhibit a stronger activity and synergy when they are combined with potent chemotherapy combinations rather than gemcitabine monotherapy. Moreover, agents that have demonstrated promising anti-stromal activity in preclinical models, especially vitamin A and D analogs, warrant clinical testing and could extend the therapeutic armamentarium in the future.
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